The Gastrointestinal Cancer (GI) Program of the Mayo Clinic Cancer Center (MCCC) continues to make significant contributions in the areas of basic, translational, and clinical research by using a multidisciplinary and interactive team approach. The primary objective of the GI Program is to use novel observations, mechanistic insights and research outcomes to benefit patients with GI cancers or at risk for GI malignancies, including those from our catchment area. This work is accomplished through robust intra- and interprogrammatic interactions focused on 4 Aims: 1) application of early detection approaches, 2) identification and evaluation of predictive or prognostic biomarkers, 3) role of the tumor microenvironment and microbiome in cancer development and progression, and 4) individualized therapeutic strategies.
Aim 3 is a new and evolving effort that builds upon an existing base of NCI-funded investigators in these fields of research, and interacts with the Microbiome Program within the Mayo Clinic Center for Individualized Medicine to expand the existing germ-free mouse facility and a metabolomics core lab. The GI Program consists of 54 members from 17 departments. Our GI Program developed a SPORE grant in Pancreatic Cancer where major contributions and interactions continue. The GI Program also developed a Hepatobiliary (HB) SPORE proposal that received a highly competitive score with a funding decision expected in mid-2018. As a result of this score, the MCCC was awarded a CCSG supplement of $750K from the NCI with an aim to maintain the infrastructure for liver cancer research. Our NIH-funded research platform and portfolio of innovative clinical trials is expanding and benefits from interactions across the 3 MCCC sites and with other multi-institutional networks; these interactions are enhancing accrual. The GI research program is supported by total direct funding of $10.2M ($5.1M peer-reviewed, with 69% from NCI). Since 2013, Program members have contributed more than 871 publications to the literature, of which 28% represent intraprogrammatic and 31% reflect interprogrammatic collaborations; 21% are in journals with an impact factor ?10. These publications reflect numerous scientific accomplishments and discoveries, several of which have been practice changing. Formal mentoring of junior faculty continues with an increased effort to provide pilot grant funding to our investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications